Banach M, Lautenschläger C, Kellner P, Soukup J
Department of Anaesthesiology and Intensive Care Medicine, Martin-Luther-University, Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany.
Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Magdeburger-Straße 8, 06112, Halle (Saale), Germany.
Med Klin Intensivmed Notfmed. 2018 Mar;113(2):101-107. doi: 10.1007/s00063-017-0276-y. Epub 2017 Mar 31.
Thrombocytosis is a common phenomenon in critically ill patients. Although thrombocytosis is an independent risk factor for complications, it does not seem to influence mortality in intensive care (ICU) patients.
Our investigation aimed to evaluate the etiological and clinical relevance of a platelet count greater than 450 × 10/l in ICU patients.
Patients admitted for a minimum of 4 days to an interdisciplinary ICU during a 45-month period were enrolled in this retrospective observational study. Thrombocytopenic patients (platelet count <150 × 10/l in at least one measurement) were excluded. The study patients were divided into two groups: thrombocytosis group (thrombocytes >450 × 10/l in at least one measurement) and control group (thrombocytes = 150 - 450 × 10/l during ICU stay). Univariate and multiple regression analysis were used to determine the influence of severe co-morbidities on the development of thrombocytosis and the association of elevated platelet count with thrombotic embolism, length of stay (LOS) in ICU, and mortality.
A total of 307 patients were analyzed, of whom thrombocytosis was observed in 119 cases. Independent risk factors for the development of thrombocytosis included SIRS, mechanical ventilation, and acute bleeding. Increasing age reduced the risk of thrombocytosis. Thromboembolism occurred in 16 patients (13.4%) with an elevated platelet count and only in nine patients (4.7%) with physiological platelet values (OR: 3.1; 95% CI: 1.3-7.2; p = 0.009). Mean duration of LOS was significantly longer in patients with thrombocytosis (25.2 vs.11.7 days, p < 0.0001). Elevated platelet count showed a negative correlation with ICU mortality (OR: 0.32; 95%-CI: 0.12-0.83; p = 0.019).
In our retrospective analysis the occurrence of thrombocytosis in a cohort of interdisciplinary ICU patients was associated with a higher rate of complications and longer LOS in the ICU. Despite these findings, thrombocytosis seems to reduce mortality in critical ill patients.
血小板增多症在重症患者中是一种常见现象。尽管血小板增多症是并发症的独立危险因素,但它似乎并不影响重症监护病房(ICU)患者的死亡率。
我们的研究旨在评估ICU患者血小板计数大于450×10⁹/L的病因及临床相关性。
本回顾性观察研究纳入了在45个月期间入住跨学科ICU至少4天的患者。排除血小板减少症患者(至少一次测量血小板计数<150×10⁹/L)。研究患者分为两组:血小板增多症组(至少一次测量血小板>450×10⁹/L)和对照组(ICU住院期间血小板计数=150 - 450×10⁹/L)。采用单因素和多因素回归分析来确定严重合并症对血小板增多症发生的影响,以及血小板计数升高与血栓栓塞、ICU住院时间(LOS)和死亡率之间的关联。
共分析了307例患者,其中119例观察到血小板增多症。血小板增多症发生的独立危险因素包括全身炎症反应综合征(SIRS)、机械通气和急性出血。年龄增加会降低血小板增多症的风险。血小板计数升高的患者中有16例(13.4%)发生血栓栓塞,而血小板值正常的患者中仅有9例(4.7%)发生(比值比:3.1;95%可信区间:1.3 - 7.2;p = 0.009)。血小板增多症患者的平均住院时间明显更长(25.2天对11.7天,p < 0.0001)。血小板计数升高与ICU死亡率呈负相关(比值比:0.32;95%可信区间:0.12 - 0.83;p = 0.019)。
在我们的回顾性分析中,跨学科ICU患者队列中血小板增多症的发生与更高的并发症发生率和更长的ICU住院时间相关。尽管有这些发现,但血小板增多症似乎能降低重症患者的死亡率。